PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
17.28
+0.28 (1.64%)
Apr 25, 2025, 12:30 PM EDT - Market open
PureTech Health Revenue
PureTech Health had revenue of $288.00K in the half year ending June 30, 2024, a decrease of -95.90%. This brings the company's revenue in the last twelve months to $468.00K, down -96.01% year-over-year. In the year 2023, PureTech Health had annual revenue of $3.33M, down -78.68%.
Revenue (ttm)
$468.00K
Revenue Growth
-96.01%
P/S Ratio
872.44
Revenue / Employee
$5,200
Employees
90
Market Cap
408.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
PRTC News
- 2 days ago - PureTech Health: Notice of Results - Business Wire
- 16 days ago - PureTech Appoints Peel Hunt as Joint UK Corporate Broker - Business Wire
- 18 days ago - PureTech Health plc Statement Regarding Press Speculation - Business Wire
- 6 weeks ago - PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair - Business Wire
- 2 months ago - PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform - Business Wire
- 3 months ago - PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine - Business Wire
- 3 months ago - PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) - Business Wire
- 3 months ago - PureTech Appoints UBS as UK Corporate Broker - Business Wire